Ep 12: Chris Gibson on Building a Platform Biotech and The Future of R&D

from Vital Signs with Jacob Effron and Nikhil Krishnan · host Redpoint Ventures

Jacob sits down with Chris Gibson, the co-founder and CEO of Recursion, to discuss how Recursion predicted drugs that would be effective for COVID, his take on different techbio business models, what pharma R&D will look like in 25 years and more.

Episode metadata supplied by the publisher feed · Published Dec 14, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Ep 12: Chris Gibson on Building a Platform Biotech and The Future of R&D

0:00 39:19

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Vital Signs with Jacob Effron and Nikhil Krishnan?

This episode is 39 minutes long.

When was this Vital Signs with Jacob Effron and Nikhil Krishnan episode published?

This episode was published on December 14, 2022.

Can I download this Vital Signs with Jacob Effron and Nikhil Krishnan episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!